Kyverna Therapeutics (KYTX) Projected to Post Quarterly Earnings on Wednesday

Kyverna Therapeutics (NASDAQ:KYTX) is expected to release its Q4 2025 results before the market opens on Wednesday, April 1st. Analysts expect Kyverna Therapeutics to post earnings of ($0.80) per share for the quarter. Interested persons are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Friday, April 3, 2026 at 4:00 PM ET.

Kyverna Therapeutics Price Performance

NASDAQ KYTX opened at $7.64 on Wednesday. The company’s 50 day simple moving average is $8.34 and its two-hundred day simple moving average is $7.55. Kyverna Therapeutics has a 1 year low of $1.78 and a 1 year high of $13.67. The stock has a market capitalization of $334.63 million, a PE ratio of -2.05 and a beta of 3.32.

Hedge Funds Weigh In On Kyverna Therapeutics

A number of institutional investors have recently made changes to their positions in KYTX. Public Employees Retirement System of Ohio purchased a new stake in shares of Kyverna Therapeutics during the 3rd quarter valued at $28,000. Qube Research & Technologies Ltd purchased a new position in Kyverna Therapeutics in the second quarter worth $43,000. Rhumbline Advisers grew its position in Kyverna Therapeutics by 22.0% in the first quarter. Rhumbline Advisers now owns 31,614 shares of the company’s stock worth $61,000 after acquiring an additional 5,694 shares in the last quarter. Ameriprise Financial Inc. bought a new position in Kyverna Therapeutics in the third quarter valued at $77,000. Finally, Bank of America Corp DE increased its stake in Kyverna Therapeutics by 41.6% in the fourth quarter. Bank of America Corp DE now owns 21,788 shares of the company’s stock valued at $81,000 after acquiring an additional 6,400 shares during the last quarter. Institutional investors own 18.08% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Kyverna Therapeutics in a report on Monday, December 29th. Wall Street Zen lowered Kyverna Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday. Wells Fargo & Company boosted their target price on Kyverna Therapeutics from $31.00 to $33.00 and gave the stock an “overweight” rating in a research report on Tuesday, December 16th. Finally, Morgan Stanley set a $33.00 target price on Kyverna Therapeutics in a research note on Monday, December 15th. Four equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $28.67.

About Kyverna Therapeutics

Kyverna Therapeutics is a clinical‐stage biotechnology company dedicated to developing engineered regulatory T‐cell (Treg) therapies for the treatment of autoimmune and inflammatory diseases. Leveraging a proprietary platform for the isolation, expansion and modification of Treg cells, the company aims to restore immune homeostasis in patients by delivering antigen‐specific cell therapies that selectively target diseased tissues while minimizing systemic immunosuppression.

The company’s lead programs include an allogeneic Treg candidate in clinical development for ulcerative colitis, with additional preclinical assets focused on rheumatoid arthritis and other chronic inflammatory conditions.